Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1989 1
1990 2
1991 4
1992 2
1993 3
1994 3
1995 2
1996 7
1997 5
1998 4
1999 3
2000 6
2001 2
2002 7
2003 4
2004 6
2005 10
2006 14
2007 9
2008 8
2009 11
2010 13
2011 6
2012 9
2013 10
2014 17
2015 7
2016 12
2017 13
2018 8
2019 9
2020 16
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

218 results
Results by year
Filters applied: . Clear all
Page 1
Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?
Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, Strafella AP, Singleton AB, Barker RA, Kieburtz K, Olanow CW, Lozano A, Kordower JH, Cedarbaum JM, Brundin P, Standaert DG, Lang AE. Espay AJ, et al. Among authors: kieburtz k. Neurology. 2020 Mar 17;94(11):481-494. doi: 10.1212/WNL.0000000000009107. Epub 2020 Feb 26. Neurology. 2020. PMID: 32102975 Free PMC article. Review.
Deep Phenotyping of Parkinson's Disease.
Dorsey ER, Omberg L, Waddell E, Adams JL, Adams R, Ali MR, Amodeo K, Arky A, Augustine EF, Dinesh K, Hoque ME, Glidden AM, Jensen-Roberts S, Kabelac Z, Katabi D, Kieburtz K, Kinel DR, Little MA, Lizarraga KJ, Myers T, Riggare S, Rosero SZ, Saria S, Schifitto G, Schneider RB, Sharma G, Shoulson I, Stevenson EA, Tarolli CG, Luo J, McDermott MP. Dorsey ER, et al. Among authors: kieburtz k. J Parkinsons Dis. 2020;10(3):855-873. doi: 10.3233/JPD-202006. J Parkinsons Dis. 2020. PMID: 32444562 Free PMC article. Review.
Levodopa and the progression of Parkinson's disease.
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Fahn S, et al. Among authors: kieburtz k. N Engl J Med. 2004 Dec 9;351(24):2498-508. doi: 10.1056/NEJMoa033447. N Engl J Med. 2004. PMID: 15590952 Free article. Clinical Trial.
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Doody RS, et al. Among authors: kieburtz k. N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889. N Engl J Med. 2014. PMID: 24450890 Free article. Clinical Trial.
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop.
Barker RA, Björklund A, Gash DM, Whone A, Van Laar A, Kordower JH, Bankiewicz K, Kieburtz K, Saarma M, Booms S, Huttunen HJ, Kells AP, Fiandaca MS, Stoessl AJ, Eidelberg D, Federoff H, Voutilainen MH, Dexter DT, Eberling J, Brundin P, Isaacs L, Mursaleen L, Bresolin E, Carroll C, Coles A, Fiske B, Matthews H, Lungu C, Wyse RK, Stott S, Lang AE. Barker RA, et al. Among authors: kieburtz k. J Parkinsons Dis. 2020;10(3):875-891. doi: 10.3233/JPD-202004. J Parkinsons Dis. 2020. PMID: 32508331 Free PMC article. Review.
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A; LCIG Horizon Study Group. Olanow CW, et al. Among authors: kieburtz k. Lancet Neurol. 2014 Feb;13(2):141-9. doi: 10.1016/S1474-4422(13)70293-X. Epub 2013 Dec 20. Lancet Neurol. 2014. PMID: 24361112 Free PMC article. Clinical Trial.
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F; Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators. Warren Olanow C, et al. Among authors: kieburtz k. Mov Disord. 2013 Jul;28(8):1064-71. doi: 10.1002/mds.25364. Epub 2013 Apr 29. Mov Disord. 2013. PMID: 23630119 Clinical Trial.
Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.
Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Singleton A, Shaw LM, Trojanowski JQ, Frasier M, Simuni T, Iranzo A, Oertel W, Siderowf A, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Marek K, Galasko D; PPMI study. Mollenhauer B, et al. Among authors: kieburtz k. Mov Disord. 2019 Sep;34(9):1354-1364. doi: 10.1002/mds.27806. Epub 2019 Jul 30. Mov Disord. 2019. PMID: 31361367 Free PMC article.
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten SJ, Bressman S, Marek K; PPMI Investigators. Simuni T, et al. Among authors: kieburtz k. Lancet Neurol. 2020 Jan;19(1):71-80. doi: 10.1016/S1474-4422(19)30319-9. Epub 2019 Oct 31. Lancet Neurol. 2020. PMID: 31678032 Free PMC article.
218 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page